BTMD
biote Corp. NASDAQ Listed Apr 28, 2021$1.48
-9.20%
vs $1.63
Mkt Cap $65.3M
52w Low $1.27
8.9% of range
52w High $3.62
50d MA $2.19
200d MA $2.22
P/E (TTM)
11.2x
EV/EBITDA
5.6x
P/B
—
Debt/Equity
-1.9x
ROE
-46.2%
P/FCF
1.8x
RSI (14)
20.80
ATR (14)
$0.18
Beta
1.29
50d MA
$2.19
200d MA
$2.22
Avg Volume
346.6K
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
1875 West Walnut Hill Lane · Irving, TX 75038 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | AMC | 0.03 | -0.23 | -962.5% | 2.26 | -15.5% | -27.9% | — | — | — | — | — |
| May 6, 2026 | AMC | 0.09 | 0.06 | -33.3% | 2.20 | -4.5% | -5.0% | +4.3% | +1.4% | -0.5% | -7.7% | — |
| Mar 11, 2026 | AMC | 0.05 | 0.06 | +20.0% | 1.72 | -3.5% | -10.5% | -9.1% | -0.7% | -2.2% | +0.0% | — |
| Nov 5, 2025 | AMC | 0.05 | 0.22 | +340.0% | 2.93 | +1.7% | -3.1% | -4.6% | -9.2% | +6.1% | +1.1% | — |
| Aug 6, 2025 | AMC | 0.06 | 0.10 | +66.7% | 3.86 | -17.6% | -24.4% | -1.4% | -2.1% | +2.5% | +6.2% | — |
| May 7, 2025 | AMC | 0.06 | 0.08 | +33.3% | 3.34 | +10.5% | +12.0% | +7.0% | -0.2% | -2.0% | +0.8% | — |
| Mar 12, 2025 | AMC | 0.09 | 0.10 | +11.1% | 4.10 | -9.8% | -25.1% | +22.5% | +6.4% | +1.8% | +3.7% | — |
| Nov 12, 2024 | AMC | 0.09 | 0.33 | +266.7% | 5.52 | +6.9% | +21.7% | -2.2% | -18.0% | +14.3% | -1.1% | — |
| Aug 8, 2024 | AMC | 0.09 | 0.14 | +55.6% | 6.77 | -1.5% | -18.9% | -2.9% | +7.5% | +2.8% | +2.7% | — |
| May 7, 2024 | AMC | 0.05 | 0.23 | +360.0% | 5.77 | +1.9% | +5.2% | +3.0% | -2.1% | -1.8% | -1.0% | — |
| Mar 12, 2024 | AMC | 0.08 | 0.18 | +125.0% | 5.30 | +15.7% | +14.9% | +2.0% | +11.3% | -3.6% | -4.2% | — |
| Nov 7, 2023 | AMC | 0.08 | -0.11 | -237.5% | 5.81 | -5.3% | -23.8% | +1.6% | +0.7% | +6.8% | +3.1% | — |
| Aug 10, 2023 | AMC | 0.10 | 0.44 | +340.0% | 6.48 | -16.4% | -13.4% | -3.7% | -5.5% | +1.2% | -4.1% | — |
| May 9, 2023 | AMC | 0.09 | 0.94 | +944.4% | 6.40 | -18.8% | -10.8% | -3.5% | +7.3% | -3.0% | -0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 | Truist | Maintains | Buy → Buy | — | $1.97 | $1.97 | +0.0% | +6.6% | +5.7% | +0.9% | -0.9% | +0.9% |
| Mar 12 | B. Riley Securities | Maintains | Neutral → Neutral | — | $1.72 | $1.66 | -3.5% | -10.5% | -9.1% | -0.7% | -2.2% | +0.0% |
| Mar 12 | TD Cowen | Maintains | Buy → Buy | — | $1.72 | $1.66 | -3.5% | -10.5% | -9.1% | -0.7% | -2.2% | +0.0% |
| Aug 7 | B. Riley Securities | Downgrade | Buy → Neutral | — | $3.86 | $3.18 | -17.6% | -24.4% | -1.4% | -2.1% | +2.5% | +6.2% |
| Mar 13 | Craig-Hallum | Maintains | Buy → Buy | — | $4.10 | $3.70 | -9.8% | -25.1% | +22.5% | +6.4% | +1.8% | +3.7% |
| Mar 13 | Roth MKM | Maintains | Buy → Buy | — | $5.30 | $6.13 | +15.7% | +14.9% | +2.0% | +11.3% | -3.6% | -4.2% |
| Jan 18 | Roth MKM | Maintains | Buy → Buy | — | $4.63 | $4.27 | -7.8% | -13.6% | -1.8% | -3.6% | +0.0% | +1.3% |
| Jan 18 | Truist | Maintains | Buy → Buy | — | $4.63 | $4.27 | -7.8% | -13.6% | -1.8% | -3.6% | +0.0% | +1.3% |
| Aug 15 | TD Cowen | Maintains | Outperform → Outperform | — | $5.41 | $5.40 | -0.1% | -5.5% | +1.2% | -4.1% | -4.6% | +4.9% |
| Aug 14 | Roth MKM | Maintains | Buy → Buy | — | $5.61 | $5.60 | -0.2% | -3.7% | -5.5% | +1.2% | -4.1% | -4.6% |
| Mar 30 | Roth MKM | Maintains | Buy → Buy | — | $5.35 | $5.34 | -0.2% | +5.8% | +9.4% | -6.3% | -0.2% | +1.6% |
| Sep 27 | Truist | Maintains | Buy → Buy | — | $4.21 | $4.33 | +2.9% | -1.2% | -0.7% | +0.5% | +3.1% | +1.9% |
| Jun 24 | TD Cowen | Maintains | Outperform → Outperform | — | $3.45 | $3.39 | -1.7% | -0.9% | +3.8% | -0.6% | +0.6% | +6.2% |
| Jun 23 | Roth Capital | Maintains | Buy → Buy | — | $3.57 | $3.57 | +0.0% | -3.4% | -0.9% | +3.8% | -0.6% | +0.6% |
No insider trades available.
8-K · 5.02
!!! Very High
biote Corp. -- 8-K 5.02: Executive Change
Jun 2
8-K · 2.02
!! High
biote Corp. -- 8-K 2.02: Earnings Results
biote Corp. reported Q1 2026 financial results, with the company's earnings announcement providing investors updated insight into operational performance and financial condition for the quarter ending March 31.
May 6
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
BTMD disclosed forward-looking statements about future revenue projections via Regulation FD, signaling management confidence in growth but creating legal risk if guidance isn't achieved.
Apr 3
8-K
Unknown — 8-K Filing
BTMD's 2025 revenue grew to $192.2M with strong 71.5% gross margins and $31.6M net income, demonstrating profitable scaling that should attract value investors seeking biotech companies with sustainable earnings growth.
Mar 11
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,113,855 | $2M | New | Mar 2026 |
| 2 | Morgan Stanley | 479,472 | $1M | Added | Dec 2025 |
| 3 | Acadian Asset Management Llc | 697,855 | $938K | Added | Mar 2026 |
| 4 | Rice Hall James & Associates, Llc | 240,829 | $626K | Added | Dec 2025 |
| 5 | Rothschild Wealth Llc | 146,250 | $380K | New | Dec 2025 |
| 6 | Northern Trust Corp | 269,113 | $363K | Added | Mar 2026 |
| 7 | Renaissance Technologies Llc | 265,916 | $359K | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 166,596 | $225K | New | Mar 2026 |
| 9 | Los Angeles Capital Management Llc | 101,947 | $138K | Added | Mar 2026 |
| 10 | Bank Of New York Mellon Corp | 69,673 | $94K | Reduced | Mar 2026 |
| 11 | Man Group Plc | 64,823 | $88K | Reduced | Mar 2026 |
| 12 | Bank Of America Corp /de/ | 58,846 | $79K | Added | Mar 2026 |
| 13 | Aqr Capital Management Llc | 53,659 | $72K | Added | Mar 2026 |
| 14 | Gds Wealth Management | 42,789 | $58K | — | Mar 2026 |
| 15 | Barclays Plc | 42,719 | $58K | Reduced | Mar 2026 |
| 16 | Nuveen, Llc | 36,459 | $49K | — | Mar 2026 |
| 17 | Franklin Resources Inc | 29,928 | $40K | Added | Mar 2026 |
| 18 | Fmr Llc | 29,641 | $40K | Added | Mar 2026 |
| 19 | Ubs Group Ag | 25,728 | $35K | Added | Mar 2026 |
| 20 | Jpmorgan Chase & Co | 19,452 | $25K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$65.3M
Enterprise Value
$130.9M
P/E (TTM)
11.15x
Forward P/E
5.10x
PEG Ratio
0.00x
P/B
—
P/S
0.36x
P/FCF
1.80x
EV/EBITDA
5.58x
Shares Out
36.7M
Financials (TTM)
Revenue
$183.5M
Net Income
$5.9M
EBITDA
$23.5M
Free Cash Flow
$30.2M
Op Cash Flow
$35.2M
EPS Basic
$0.86
EPS Diluted
$0.12
EPS Forward
$0.29
Gross Margin
60.2%
Op Margin
8.0%
Net Margin
3.2%
Balance Sheet
Total Assets
$107.6M
Total Liab.
$158.0M
Total Equity
-$50.4M
Cash
$24.1M
LT Debt
$100.8M
Book Value/Sh
$-1.61
Debt/Equity
-1.88x
Current Ratio
1.22
Quick Ratio
0.79
Returns & Growth
ROE
-46.2%
ROA
25.1%
ROIC
43.0%
Rev Growth YoY
-2.5%
EPS Growth YoY
+833.8%
Price Returns
2W
-35.1%
1M
-34.5%
3M
-32.1%
6M
-33.6%
12M
-48.6%
Technicals
52W High
$3.62
52W Low
$1.27
50d MA
$2.19
200d MA
$2.22
RSI (14)
20.80
ATR (14)
$0.18
Beta
1.29
Avg Volume
347K
Dividends
Div Rate
$0.06
Div Yield
2.5%
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.25
High
$4.00
Low
$2.50
Median
$3.25
Data updated apr 24, 2026 11:06pm
· Source: financialmodelingprep.com